$Azitra(AZTR.US)$Azitra Received Notice Of Allowance For U.S. Patent Application Titled 'THERAPEUTIC TREATMENT OF SKIN DISEASE WITH RECOMBINANT COMMENSAL SKIN MICROORGANISMS'
$Azitra(AZTR.US)$ NEWS Azitra Presents Preclinical Data From ATR-04 At Society Of Investigative Dermatology Annual Meeting Benzinga· 37 mins ago1min Azitra (AZTR.US ATR-04 is in development for epidermal growth factor receptor inhibitor (EGFRi)-induced dermal toxicity, which affects approximately 150,000 patients in the US Reduces methicillin-resistant S. aureus by 99% on ex vivo pig skin Reduces IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human ski...
Azitra, Inc. Announces Breakthrough in Netherton Syndrome Treatment with ATR-12. Azitra, Inc., a company in the field of clinical-stage biopharmaceuticals dedicated to pioneering precision dermatology, is at the horizon of an exciting development in the treatment of Netherton Syndrome. On May 10, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, MD, Azitra u...
$Azitra(AZTR.US)$ NEWS Azitra, Inc. Announces Positive Preclinical Data of Atr-12 and Clinical Design in Netherton Syndrome Presented at the Asgct Annual Meeting
Onlyupupup : 你是什麼意思被認可?由誰?